...
首页> 外文期刊>EJNMMI Research >[ 18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer
【24h】

[ 18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer

机译:[ 18 f] ml-10宠物成像未能评估对新辅助化疗的早期反应,在三重阴性乳腺癌的临床前模型中

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose Pathological complete response to the neoadjuvant therapy (NAT) for triple negative breast cancer (TNBC) is predictive of prolonged patient survival. Methods for early evaluation of NAT efficiency are still needed, in order to rapidly adjust the therapeutic strategy in case of initial non-response. One option for this is molecular imaging of apoptosis induced by chemotherapy. Therefore, we investigated the capacity of [ ~(18)F]ML-10 PET imaging, an apoptosis radiotracer, to detect tumor cell apoptosis and early predict the therapeutic response of human TNBC. Results Initially, the induction of apoptosis by different therapies was quantified. We confirmed, in vitro, that paclitaxel or epirubicin, the fundamental cytotoxic drugs for breast cancer, induce apoptosis in TNBC cell lines. Exposure of TNBC models MDA-MB-231 and MDA-MB-468 to these drugs induced a significant increase ( p & 0.01) of the apoptotic hallmarks: DNA fragmentation, membrane phospholipid scrambling, and PARP activation. Secondarily, apoptotic fraction was compared to the intracellular accumulation of the radiotracer. [ ~(18)F]ML-10 accumulated in the apoptotic cells after 72 h of treatment by paclitaxel in vitro; this accumulation positively correlated with the apoptotic fraction. In vivo, [ ~(18)F]ML-10 was rapidly cleared from the nontarget organs and mainly eliminated by the kidneys. Comparison of the in vivo [ ~(18)F]FDG, [ ~(18)F]FMISO, and [ ~(18)F]ML-10 uptakes revealed that the tumor accumulation of [ ~(18)F]ML-10 was directly related to the tumor hypoxia level. Finally, after the in vivo treatment of TNBC murine xenografts by paclitaxel, apoptosis was well induced, as demonstrated by the cleaved caspase-3 levels; however, no significant increase of [ ~(18)F]ML-10 accumulation in the tumors was observed, either on day 3 or day 6 after the end of the treatment. Conclusions These results highlighted that PET imaging using [ ~(18)F]ML-10 allows the visualization of apoptotic cells in TNBC models. Nevertheless, the increase of the chemotherapy-induced apoptotic response when using paclitaxel could not be assessed using this radiotracer in our mouse model.
机译:目的对三重阴性乳腺癌(TNBC)对新辅助治疗(NAT)的病理完全反应预测患者存活率长。仍需要早期评估NAT效率的方法,以便在初始非反应的情况下快速调整治疗策略。一种选择是通过化疗诱导的细胞凋亡的分子成像。因此,我们调查了[〜(18)F] ML-10 PET成像,细胞凋亡放射性机构的能力,以检测肿瘤细胞凋亡和早期预测人TNBC的治疗反应。结果最初,量化了不同疗法的诱导凋亡。我们确认,体外,紫杉醇或同性素,乳腺癌的基本细胞毒性药物,诱导TNBC细胞系中的细胞凋亡。 TNBC模型的暴露MDA-MB-231和MDA-MB-468对这些药物的显着增加(P <0.01)的凋亡标志:DNA碎片,膜磷脂加扰和PARP活化。其次,将凋亡级分与放射体机的细胞内积聚进行了比较。 [〜(18)f]在凋亡细胞中累积在凋亡细胞中累积在72小时后,PACLITAXEL体外治疗;这种积极与凋亡级分相关。在体内,从Nontarget Organs迅速清除[〜(18)f] ml-10,主要由肾脏消除。体内[〜(18)F] FDG,[〜(18)F] FMISO的比较,[〜(18)F] ML-10上唇显示[〜(18)F] ML-的肿瘤积累10与肿瘤缺氧水平直接相关。最后,在通过紫杉醇的TNBC鼠异种移植物的体内处理之后,诱导细胞凋亡,如裂解的caspase-3水平证明;然而,在治疗结束后的第3天或第6天,观察到肿瘤中[〜(18)F] ML-10积累的显着增加。结论这些结果突出显示使用[〜(18)F] ML-10的PET成像允许在TNBC模型中可视化凋亡细胞。然而,在我们的小鼠模型中使用该放射机构不能评估使用紫杉醇时的化疗诱导的凋亡响应的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号